RU2008119096A - Терапевтический агент - Google Patents
Терапевтический агент Download PDFInfo
- Publication number
- RU2008119096A RU2008119096A RU2008119096/13A RU2008119096A RU2008119096A RU 2008119096 A RU2008119096 A RU 2008119096A RU 2008119096/13 A RU2008119096/13 A RU 2008119096/13A RU 2008119096 A RU2008119096 A RU 2008119096A RU 2008119096 A RU2008119096 A RU 2008119096A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- ramp
- agent according
- protein
- sequence
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 11
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 20
- 125000000539 amino acid group Chemical group 0.000 claims abstract 12
- 102000056906 Calcitonin Receptor-Like Human genes 0.000 claims abstract 9
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 claims abstract 9
- 238000004519 manufacturing process Methods 0.000 claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract 9
- 150000001413 amino acids Chemical group 0.000 claims abstract 6
- 102000003839 Human Proteins Human genes 0.000 claims abstract 5
- 108090000144 Human Proteins Proteins 0.000 claims abstract 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- 102000015146 Receptor Activity-Modifying Proteins Human genes 0.000 claims abstract 3
- 108010064300 Receptor Activity-Modifying Proteins Proteins 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 102000005962 receptors Human genes 0.000 claims abstract 3
- 108020003175 receptors Proteins 0.000 claims abstract 3
- 102000004379 Adrenomedullin Human genes 0.000 claims abstract 2
- 101800004616 Adrenomedullin Proteins 0.000 claims abstract 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims abstract 2
- 230000004663 cell proliferation Effects 0.000 claims abstract 2
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 230000003993 interaction Effects 0.000 claims abstract 2
- 239000003446 ligand Substances 0.000 claims abstract 2
- 201000008968 osteosarcoma Diseases 0.000 claims abstract 2
- 230000035755 proliferation Effects 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical class 0.000 claims 24
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000002068 genetic effect Effects 0.000 claims 4
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 201000009101 diabetic angiopathy Diseases 0.000 claims 2
- 102000017631 Calcitonin-like Human genes 0.000 claims 1
- 108050005865 Calcitonin-like Proteins 0.000 claims 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050294 human RAMP3 Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0521139.6 | 2005-10-18 | ||
| GBGB0521139.6A GB0521139D0 (en) | 2005-10-18 | 2005-10-18 | Therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008119096A true RU2008119096A (ru) | 2009-11-27 |
Family
ID=35451928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008119096/13A RU2008119096A (ru) | 2005-10-18 | 2006-10-18 | Терапевтический агент |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20080279857A1 (enExample) |
| EP (2) | EP2402372A3 (enExample) |
| JP (4) | JP2009515827A (enExample) |
| KR (1) | KR20080059449A (enExample) |
| CN (2) | CN105037551A (enExample) |
| AU (1) | AU2006305654B2 (enExample) |
| CA (1) | CA2624931A1 (enExample) |
| GB (1) | GB0521139D0 (enExample) |
| RU (1) | RU2008119096A (enExample) |
| WO (1) | WO2007045927A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| US8858915B2 (en) | 2007-11-26 | 2014-10-14 | Japan Science & Technology Agency | Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome |
| FR2934597B1 (fr) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
| JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| WO2011022667A2 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Catalytic domains from lysyl oxidase and loxl2 |
| EP2531217A4 (en) | 2010-02-04 | 2013-11-27 | Gilead Biologics Inc | ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF |
| FR2964103B1 (fr) | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| JP5806859B2 (ja) * | 2011-06-08 | 2015-11-10 | ポーラ化成工業株式会社 | スクリーニング方法 |
| EP2589963A1 (en) | 2011-11-04 | 2013-05-08 | Université de Provence (Aix-Marseille 1) | Diagnostic and treatment of an androgen-independent prostate cancer |
| AU2015318008B2 (en) | 2014-09-15 | 2021-05-20 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
| JP6508670B2 (ja) * | 2014-12-26 | 2019-05-08 | 国立大学法人広島大学 | 軟骨変性抑制剤 |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| CN105420247B (zh) * | 2015-12-09 | 2018-09-07 | 浙江大学 | 水稻不定根控制基因crlr1的应用 |
| AU2017376400A1 (en) | 2016-12-13 | 2019-06-20 | Novozymes A/S | Methods for treating inflammatory conditions of the lungs |
| WO2019054460A1 (ja) * | 2017-09-13 | 2019-03-21 | 株式会社ジーンテクノサイエンス | 抗ｒａｍｐ２抗体 |
| MA52202A (fr) | 2018-04-02 | 2021-02-17 | Amgen Inc | Compositions d'érénumab et utilisations de celles-ci |
| EP3877413A1 (en) * | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
| GB202303531D0 (en) * | 2023-03-10 | 2023-04-26 | Fusion Antibodies Plc | Antibodies and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045153A1 (de) | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| KR100272659B1 (ko) | 1997-06-28 | 2000-12-01 | 김영환 | 반도체 소자의 금속배선 선폭 측정방법 |
| US20030055231A1 (en) * | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| US20050208487A1 (en) | 2000-05-26 | 2005-09-22 | Jens Burmeister | Immobilized nuckeic acids and uses thereof |
| WO2004050834A2 (en) * | 2002-11-27 | 2004-06-17 | Genpath Pharmaceuticals, Incorporated | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
-
2005
- 2005-10-18 GB GBGB0521139.6A patent/GB0521139D0/en not_active Ceased
-
2006
- 2006-10-18 JP JP2008536134A patent/JP2009515827A/ja active Pending
- 2006-10-18 CN CN201510206436.0A patent/CN105037551A/zh active Pending
- 2006-10-18 WO PCT/GB2006/050338 patent/WO2007045927A2/en not_active Ceased
- 2006-10-18 RU RU2008119096/13A patent/RU2008119096A/ru not_active Application Discontinuation
- 2006-10-18 CN CNA2006800477847A patent/CN101341171A/zh active Pending
- 2006-10-18 US US12/090,635 patent/US20080279857A1/en not_active Abandoned
- 2006-10-18 EP EP11162714A patent/EP2402372A3/en not_active Withdrawn
- 2006-10-18 KR KR1020087011686A patent/KR20080059449A/ko not_active Withdrawn
- 2006-10-18 CA CA002624931A patent/CA2624931A1/en not_active Abandoned
- 2006-10-18 AU AU2006305654A patent/AU2006305654B2/en not_active Ceased
- 2006-10-18 EP EP06794995A patent/EP1945670A2/en not_active Withdrawn
-
2010
- 2010-08-03 US US12/849,536 patent/US8895005B2/en not_active Expired - Fee Related
-
2012
- 2012-08-30 JP JP2012190219A patent/JP2012246309A/ja active Pending
-
2014
- 2014-09-24 JP JP2014193911A patent/JP2015003920A/ja active Pending
- 2014-10-09 US US14/511,099 patent/US9556268B2/en not_active Expired - Fee Related
-
2015
- 2015-07-02 JP JP2015133603A patent/JP2015178534A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150037344A1 (en) | 2015-02-05 |
| AU2006305654B2 (en) | 2013-07-11 |
| EP1945670A2 (en) | 2008-07-23 |
| GB0521139D0 (en) | 2005-11-23 |
| JP2015178534A (ja) | 2015-10-08 |
| US20110195076A1 (en) | 2011-08-11 |
| US8895005B2 (en) | 2014-11-25 |
| CN101341171A (zh) | 2009-01-07 |
| CA2624931A1 (en) | 2007-04-26 |
| US20080279857A1 (en) | 2008-11-13 |
| EP2402372A3 (en) | 2012-05-02 |
| WO2007045927A2 (en) | 2007-04-26 |
| US9556268B2 (en) | 2017-01-31 |
| JP2009515827A (ja) | 2009-04-16 |
| KR20080059449A (ko) | 2008-06-27 |
| JP2015003920A (ja) | 2015-01-08 |
| WO2007045927A3 (en) | 2007-08-02 |
| JP2012246309A (ja) | 2012-12-13 |
| AU2006305654A1 (en) | 2007-04-26 |
| EP2402372A2 (en) | 2012-01-04 |
| CN105037551A (zh) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008119096A (ru) | Терапевтический агент | |
| Cheng et al. | New frontiers in osteoporosis therapy | |
| Kostenuik et al. | OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | |
| Fukumoto et al. | Recent advances in the management of osteoporosis | |
| Novack | Role of NF-κB in the skeleton | |
| McClung et al. | Romosozumab in postmenopausal women with low bone mineral density | |
| Azim et al. | Bone metastasis in breast cancer: the story of RANK-ligand | |
| Otvos Jr et al. | Development of second generation peptides modulating cellular adiponectin receptor responses | |
| Johnson et al. | Coacervate delivery of HB‐EGF accelerates healing of type 2 diabetic wounds | |
| Grässel et al. | Do neuroendocrine peptides and their receptors qualify as novel therapeutic targets in osteoarthritis? | |
| KR20200085763A (ko) | 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 | |
| KR20160009575A (ko) | 심부전을 치료하기 위한 뉴레귤린의 연장 방출 | |
| Inzerillo et al. | Calcitonin: the other thyroid hormone | |
| Steen | Treatment of systemic sclerosis | |
| Yamada et al. | Role of the c domain of IGFs in synergistic promotion, with a substance P–derived peptide, of rabbit corneal epithelial wound healing | |
| US7622438B1 (en) | Protein formulation for promoting hard tissue formation | |
| Martin et al. | Abaloparatide is an anabolic, but does it spare resorption? | |
| Lewiecki | Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis | |
| Mundy | Directions of drug discovery in osteoporosis | |
| WO2004080957A3 (en) | Use of adnf polypeptides for treating anxiety and depression | |
| Whitfield et al. | Cyclization by a Specific Lactam Increases the Ability of Human Parathyroid Hormone (hPTH)‐(1–31) NH2 to Stimulate Bone Growth in Ovariectomized Rats | |
| Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
| Fink et al. | Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase | |
| Yao et al. | Aligned nanofiber nerve conduits inhibit alpha smooth muscle actin expression and collagen proliferation by suppressing TGF-β1/SMAD signaling in traumatic neuromas | |
| Tanaka et al. | Osteopontin-derived synthetic peptide SVVYGLR has potent utility in the functional regeneration of oral and maxillofacial skeletal muscles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100312 |